GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US clinical stage caner drug developer Theriva Biologics revealed that the US Food and Drug Administration (FDA) has granted Rare Pediatric Drug designation (RPDD) for VCN-01 for the treatment of retinoblastoma. 1 August 2024
Eisai and Biogen have announced that Israel has approved their Alzheimer's treatment, Leqembi (lecanemab), adding to nods in the USA, Japan, China, South Korea, and Hong Kong. 12 July 2024
Contract research and development organization (CDMO) Emergent BioSolutions has announced that Johnson & Johnson will pay $50 million to resolve claims linked to a terminated manufacturing deal for the latter’s COVID-19 vaccine. 11 July 2024
Japan’s Eisai and US biotech Biogen have announced that the Department of Health in Hong Kong has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for treatment of Alzheimer’s disease (AD). 11 July 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has announced that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes (T1D) patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care. 24 June 2024
Indian drugmaker Cipla announced that its wholly-owned subsidiary in the UK, Cipla (EU) Limited, will invest an additional 3 million euros ($3.2 million) in Ethris GmbH, a German firm delivering mRNAs directly to the respiratory system. 19 June 2024
Dutch autoimmune diseases specialist Argenx announced that results from the Phase II ALPHA study of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) show that treated patients had no clinically meaningful improvement compared to placebo on the total Malmö POTS symptom (MaPS) score and COMPASS31. 17 June 2024
The US Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for monthly Leqembi (lecanemab-irmb) intravenous (IV) maintenance dosing. 10 June 2024
The European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved Chimeric Antigen Receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) from Gilead Sciences’ Kite subsidiary. 6 June 2024
French pharma major Sanofi edged up 1% on release of new data that adds to the body of evidence demonstrating nirsevimab’s protection against respiratory syncytial virus (RSV)-related lower respiratory tract disease (LRTD) and confirm its favorable safety profile in multi-country, real-world conditions 12 May 2023
Privately-held Italian firm Angelini Pharma and Japan’s JCR Pharmaceuticals have agreed an exclusive global development and commercialization agreement for the development of biologics for epilepsy. 11 May 2023
Shares in Novavax, a US company advancing protein-based vaccines with its Matrix-M adjuvant, have increased by more than a quarter so far this week. 11 May 2023
The recent European Commission approval for Sotyktu (deucravacitinib), US pharma major Bristol Myers Squibb’s first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for adults with moderate-to-severe plaque psoriasis (PsO), has elicited comment from a leading data and analytics firm. 11 May 2023
UK-based cancer immunotherapy company Immodulon has named Richard Davies its new chairman of the board, appointed Gertjan Bartlema chief executive and brought in Peter Greaney as chief business officer. 10 May 2023
Alexion, a subsidiary of Anglo-Swedish pharma major AstraZeneca with a focus on rare diseases, has scored another win in neuromyelitis optica spectrum disorder (NMOSD). 10 May 2023
Shares of UK biotech Bicycle Therapeutics rode up 8.6% to $24.30 by mid-morning US trading, on the news of a potentially lucrative deal with Germany’s Bayer. 10 May 2023
US biotech major Gilead Sciences has prevailed in a legal battle with its country’s government over HIV pre-exposure prophylaxis (PrEP) patents. 10 May 2023
Swedish Orphan Biovitrum, also known as Sobi, has reached an agreement to acquire CTI BioPharma, a US biopharma company focused on blood related cancers and rare diseases, by means of a tender offer. 10 May 2023
Cell programming and biosecurity platform company Ginkgo Bioworks has announced a new partnership with privately-held German pharma major Boehringer Ingelheim. 10 May 2023
Announcing its first M&A deal in more than a year, California, USA-based Gilead Sciences said yesterday that it has acquired privately-held US biotech XinThera. 10 May 2023
Privately-held Chinese biotech Zion Pharma revealed that Swiss pharms giant Roche has acquired the global rights to Zion’s lead program, ZN-A-1041, an orally administered selective tyrosine kinase inhibitor targeting the human epidermal growth factor receptor 2 (HER2). 10 May 2023
US biopharma Insmed yesterday announced progress across its early-stage research programs, at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More. 10 May 2023
In line with a trend for big life science firms to divest non-core operations, medtech giant Baxter International (NYSE: BAX) is to sell off its biopharma manufacturing unit. 10 May 2023
US drugmaker EQRx had already signalled a shift away from its foundational principle to develop and deliver innovative medicines to patients at radically lower prices. 9 May 2023
The World Health Organization’s (WHO) declaration on Friday that the COVID-19 global emergency status has ended, and that the virus should now be managed alongside other infectious diseases, formally brings to an end what has been an uncertain and difficult time for much of the world. 9 May 2023